DiaMedica Therapeutics Inc. announced its plans to expand its clinical trials into preeclampsia, a hypertensive disorder of pregnancy with a significant unmet medical need and no U.S. Food and Drug Administration (FDA) approved therapeutics.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | -3.28% |
|
+36.57% | +3.87% |
Jun. 27 | Transcript : DiaMedica Therapeutics Inc. - Special Call | |
Jun. 26 | DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.87% | 112M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia